Analysts' average 12-month price target for Cellectis is $4.4.
Get informed when a big investor buys or sells
+ Follow$1.56
3 analysts in the last 4 months
High: $9 | Low: $1.3
No recommendations in the last 4 months.
Cellectis posts a target price of $4.4. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $4.4 for CLLS means covering analysts, on average, see the stock 184.2% upside of $1.56 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for CLLS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cellectis's other metric pages and overview cover the third.
Judging Cellectis against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $4.4 here, then scan peer and history charts to see if the gap is persistent.